News | ACC | February 09, 2016

Late-breaking Trial Presentations at ACC 2016

ACC late breakers

The following are the late-breaking clinical trial presentations presented at the 2016 American College of Cardiology (ACC) meeting April 2-4 in Chicago. The trials below were chosen based on the importance of their contribution to cardiovascular science. Click on the highlighted text to see the articles related to each presentation.

Joint ACC/JACC Late-Breaking Clinical Trials
April 2, 2016, 9 a.m., Main Tent (North Hall B1)

Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate Risk Patients with Aortic Stenosis: Final Results from the Randomized Placement of Aortic Transcatheter Valves (PARTNER 2A) Study. Presenter: Craig Smith. 9:05 - 9:17 am
Watch video interview on the PARTNER 2 outcomes

Blood Pressure Lowering in People at Moderate Risk. The HOPE-3 Trial. Presenter: Eva M. Lon. 9:27 - 9:37 a.m.

• Effects of Combined Lipid and BP-lowering on Cardiovascular Disease in a Moderate Risk Global Primary Prevention Population. Presenter: Salim Yusuf. 9:37 - 9:47 a.m.

 

Joint ACC/Journal of the American Medical Association Late-Breaking Clinical Trials
April 3, 2016, 8 a.m., Main Tent (North Hall B1)

• Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Events: Results of the ACCELERATE trial. Presenter: Stephen J. Nicholls. 8 - 8:10 a.m.

• Comparison of PCSK9 Inhibitor Evolocumab Versus Ezetimibe in Statin-intolerant Patients: The Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects 3 (GAUSS-3) Trial. Presenter: Steven E. Nissen. 8:15 - 8:25 a.m.

• Low-density Lipoprotein Cholesterol, Familial Hypercholesterolemia Mutation Status and Risk for Coronary Artery Disease. Presenter: Amit V. Khera. 8:30 - 8:40 a.m.

Reproducible Impact of a Global Mobile Health (mHealth) Mass-Participation Physical Activity Intervention on Step Count, Sitting Behavior and Weight: the Stepathlon Cardiovascular Health Study. Presenter: Anand Ganesan. 8:45 - 8:55 a.m.

• Involving Patients with Low Risk Chest Pain in Discharge Decisions: A Multicenter Trial. Presenter: Erik P. Hess. 9- 9:10 a.m.

 

Joint American College of Cardiology/TCT Late-Breaking Clinical Trials
April 3, 2016:

The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: DEFERred stent implantation in connection with primary PCI. Presenter: Henning Kelbæk. 10:45 - 10:55 a.m.

The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: iPOSTconditioning during primary PCI. Presenter: Thomas Engstrøm. 11 - 11:10 a.m.

• Effect Of Early Administration Of Intravenous Beta Blockers In Patients With ST-elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention. The Early-BAMI trial. Presenter: V. Roolvink. 11:15 - 11:25 a.m.

Sapien 3 Transcatheter Aortic Valve Replacement versus Surgery in Intermediate-Risk Patients with Severe Aortic Stenosis: A Propensity-Matched Comparison of One-Year Outcomes. Presenter: Vinod H. Thourani. 11:30 - 11:40 a.m.
Watch a video interview with Thourani at ACC.16

Relationship Between Procedure Volume and Outcome for Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: Insights from the STS/ACC TVT Registry. Presenter: John D. Carroll. 11:45 - 11:55 a.m.

Watch video interview with Carroll at ACC.16

 

Joint ACC/New England Journal of Medicine Late-Breaking Clinical Trials
April 4, 2016, 8 a.m., Main Tent (North Hall B1)

Antiarrhythmic Drugs for Shock-Refractory Out-of-Hospital Cardiac Arrest: The Resuscitation Outcomes Consortium Amiodarone, Lidocaine or Placebo Study. Presenter: Peter J. Kudenchuk. 8- 8:10 a.m.

• Largest Randomized Trial Demonstrates an Effective Ablation of Atrial Fibrillation: the FIRE AND ICE Trial (NCT01490814). Presenter: Karl-Heinz Kuck. 8:15 - 8:25 a.m.

A Randomized Trial of Rate Control Versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery. Presenter: A. Marc Gillinov. 8:30 - 8:40 a.m.

• The Losmapimod To Inhibit P38 MAP Kinase As a Therapeutic Target And Modify Outcomes After An Acute Coronary Syndrome (LATITUDE-TIMI 60) Trial: Primary Results Of Part A. Presenter: Michelle L. O'Donoghue. 8:45 - 8:55 a.m.

• CMX-2043 for Prevention of Contrast Induced Acute Kidney Injury: The Primary Results of the CARIN Trial. Presenter: Deepak L. Bhatt. 9 - 9:10 a.m.

 

Late-Breaking Clinical Trials
April 4, 2016, 10:45 a.m., Main Tent (North Hall B1)

Direct Renin-inhibition With Aliskiren Alone And In Combination With Enalapril, Compared With Enalapril, In Heart Failure (the ATMOSPHERE Trial). Presenter: John J. V. McMurray. 10:45 - 10:55 a.m.

• Effect of Ularitide on Short- and Long-Term Clinical Course of Patients with Acutely Decompensated Heart Failure: Primary Results of the TRUE-AHF Trial. Presenter: Milton Packer. 11 - 11:10 a.m.

The Final Results of the IxCell-DCM Stem Cell Trial: Transendocardial Injection of Ixmyelocel-T in Patients with Ischemic Dilated Cardiomyopathy. Presenter: Timothy D. Henry. 11:15 - 11:25 a.m.
Additional article on IxCell-DCM stem cell therapy

The Effect of Vagal Nerve Stimulation in Heart Failure: Primary Results of the INcrease Of VAgal TonE in chronic Heart Failure (INOVATE-HF) Trial. Presenter: Michael Robert Gold. 11:30 - 11:40 a.m.

Noninvasive Lung IMPEDANCE-Guided Pre-emptive Treatment in Chronic Heart Failure Patients: a Randomized Controlled Trial (IMPEDANCE-HF trial). Presenter: Michael Shochat. 11:45 - 11:55 a.m.

 

Late-Breaking Clinical Trials: Deep Dive II
April 4, 2016, 12:30 - 1:45 p.m.  Room S406a

Session will focus on key trial data from some of the top studies presented.

Related Content

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broa
Overlay Init